Evidence map›Paper›PMID 37065659›Full record

ArticleInternational journal of bioprinting2023

219Three-dimensional printing as a cutting-edge, versatile and personalizable vascular stent manufacturing procedure: Toward tailor-made medical devices.

Fatima Garcia-Villen, Fernando López-Zárraga, Cesar Viseras, Sandra Ruiz-Alonso, Fouad Al-Hakim, Irene Diez-Aldama, Laura Saenz-Del-Burgo, Denis Scaini, Jose Luis Pedraz

Open access · diamondAbstract read
In one paragraph

Article in International journal of bioprinting, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Back to the Basics: Bare Metal Stents.Seminars in interventional radiology · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Fatima Garcia-VillenNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
Fernando López-ZárragaDepartment of Vascular and Interventional Radiology, Álava University Hospital, Integrated Health Organization of Álava (Osakidetza), Spain.
Cesar ViserasDepartment of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada (UGR), Campus of Cartuja, 18071 s/n, Granada, Spain.
Sandra Ruiz-AlonsoNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
Fouad Al-HakimNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
Irene Diez-AldamaNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
Laura Saenz-Del-BurgoNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
Denis ScainiJoint Research Laboratory (JRL). School of Pharmacy, University of the Basque Country (UPV/ EHU), 01006, Vitoria-Gasteiz, Spain.
Jose Luis PedrazNanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006, Vitoria-Gasteiz, Spain.
University of the Basque Country · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESHospital Universitario Araba · ESUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular stents (VS) have revolutionized the treatment of cardiovascular diseases, as evidenced by the fact that the implantation of VS in coronary artery disease (CAD) patients has become a routine, easily approachable surgical intervention for the treatment of stenosed blood vessels. Despite the evolution of VS throughout the years, more efficient approaches are still required to address the medical and scientific challenges, especially when it comes to peripheral artery disease (PAD). In this regard, three-dimensional (3D) printing is envisaged as a promising alternative to upgrade VS by optimizing the shape, dimensions and stent backbone (crucial for optimal mechanical properties), making them customizable for each patient and each stenosed lesion. Moreover, the combination of 3D printing with other methods could also upgrade the final device. This review focuses on the most recent studies using 3D printing techniques to produce VS, both by itself and in combination with other techniques. The final aim is to provide an overview of the possibilities and limitations of 3D printing in the manufacturing of VS. Furthermore, the current situation of CAD and PAD pathologies is also addressed, thus highlighting the main weaknesses of the already existing VS and identifying research gaps, possible market niches and future directions.

Indexed as

AtherosclerosisCoronary artery diseaseEndovascular prosthesisPeripheral artery diseaseStentThree-dimensional printing

Identifiers

PMID37065659
PMCPMC10090821
OpenAlexW4319867391

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.